FDA Approves INOVIO’s First DNA Immunotherapy for Rare Disease
PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) has secured U.S. Food and Drug Administration accelerated approval for VOCERYQ, the first plasmid DNA-based immunotherapy authorized in the United States, giving the …
FDA Approves INOVIO’s First DNA Immunotherapy for Rare Disease Read More